Navigation Links
VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
Date:2/6/2008

Disease Altering Treatment Shows Ability to Prevent HIV from Replicating

GAITHERSBURG, Md., Feb. 6 /PRNewswire/ -- VIRxSYS Corporation, a privately held company developing gene therapies for HIV and genetic diseases, presented results from its Phase II trial of VRX496, a gene therapy for the treatment of AIDS, at the 2008 Annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, MA.

"This appears to be a significant demonstration of slowing and possibly halting the replication of the infectious HIV virus in humans," said Dr. Gary Blick, Medical Director, Circle Medical LLC. "VRX496 appears to cause wt-HIV particles to lose their envelopes and the in vivo pressure delivered by a patient's own modified cells leads to massive quasispecie reductions and production of impaired and less replicative virions. This treatment shows tremendous promise."

VRX496 has the potential to change HIV/AIDS care. Currently there are a variety of drugs available for HIV-infected patients, but all have long-term complications. To date, there have been no reported adverse events in any patient receiving VRX496 in clinical trials. In addition, VRX496 does not require daily administration.

"We are proving the effectiveness of our lentiviral vector approach in attacking HIV," said Dr. Laurent Humeau, VP of R&D for VIRxSYS. "Our lentiviral vector VRX496 appears to sustain expression of the RNA antisense targeting the HIV envelope for a long period of time, with a measurable effect on the HIV replicative fitness up to 3 years following a single injection. We believe this will prove to be an important step in the treatment of this disease."

VRX496 is a different viral vector than those used in previous gene therapy trials. VRX496 is derived from HIV-1 itself and has it disease-causing elements removed. Currently, VRX496 is being investigated as a therapeutic treatment (a treatment for those already infected with HIV). Unlike other vir
'/>"/>

SOURCE VIRxSYS Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIRxSYS and Lentigen Announce Litigation Settlement
2. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
3. Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research
4. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
5. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
6. Xenon Announces Appointment of VP, Discovery Research
7. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
8. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
9. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
10. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
11. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Egenix, Inc. is pleased to announce that ... the Board, to succeed Donald Fresne ; Mr. Fresne ... as a member of the Board.  In recognition of the ... company over almost twenty years, the Board designated Mr. Fresne ... has established a Search Committee to find a suitable replacement ...
(Date:12/17/2014)... “Never say, ‘I cannot do ... Department of Physics, advises young women pursuing careers ... SPIE Women in Optics 18-month planner ... ask questions.” , In the annual planner, women ... ranging from university professor and laboratory researcher to ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... first quarter of 2005 amid poor overall stock market performance. ... larger cap life science companies. Note that these results dont ... have noticed headlines at the end of last week when ... (Bextra) off the market. , ,This stronger-than-expected action by the ...
... Assembly voted late Tuesday night to amend a bill ... on newly created human embryonic stem cells would be ... excludes firms that do any research involving the destruction ... stem cells from them after August 9, 2001. ...
... house packed the Securities and Exchange Commission headquarters on ... onerous section of The Sarbanes-Oxley Act of 2002 (or ... of public companies, auditors, investors, and members of the ... the section now that many large public companies have ...
Cached Biology Technology:Midwest large-cap life-science sector is solid in first quarter 2Bill would deny tax credits to firms creating stem-cell cultures 2Star panel re-evaluates Sarbanes-Oxley one year in at SEC headquarters 2Star panel re-evaluates Sarbanes-Oxley one year in at SEC headquarters 3Star panel re-evaluates Sarbanes-Oxley one year in at SEC headquarters 4
(Date:11/18/2014)... 2014  The Secure Identity & Biometrics Association ... announce the formation of The Airport Entry and ... Identity and Biometric Entry and Exit Solutions Framework ... support from BORDERPOL, the international non-profit organization that ... expertise regarding border security, traveler and migration systems. ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock Inc. ... solutions, and MorphoTrust USA (Safran), a ... today announced a strategic partnership to offer comprehensive ... vehicle administration (MVA), airport screening and financial services ... solutions, MorphoTrust serves consumers through a nationwide network ...
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... satellite swept over the Gulf of Mexico oil spill from ... Spectroradiometer instrument captured sunglints in a visible image of the ... sunglint within the area of the gray-beige colored spill. Sunglint ... surface. In calm waters, the rounded image of the sun ...
... study by a team of researchers led by Jeffrey ... University of Notre Dame, is using Nuclear Magnetic Resonance ... the dynamic flexibility of drugs and their targets. ... the American Chemical Society, contributes to the growing attention ...
... is in your drinking water? A study by a University ... next time you fill up that glass of tap water. ... the College of Arts and Sciences, sampled eight community water ... and bacteria linked to human feces that could potentially cause ...
Cached Biology News:Nuclear magnetic resonance aids in drug design 2UT study finds viruses in untreated East Tennessee drinking water 2
... The Precision Slide Table is designed ... double bore design provides maximum force output ... has four sets of stainless steel ball ... Bumpers or self-compensating shock absorbers provide ...
... Serum is obtained from non-demolished ... healthy, fasted donors. The donors ... way and are maintained on ... Total Protein Concentration : 85 ...
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... CyScribe First-Strand cDNA Labeling Kit with ... For the generation and purification of ... packaged together for complete cDNA labeling ... be used for performing labeling reactions ...
Biology Products: